R R

What Is a Nanoparticle Drug?

A nanoparticle drug is a drug product in which the active ingredient or a delivery material is present in particles with nanoscale dimensions or related nanoscale properties. The particles can carry, protect, solubilize, or control the release of a medicine. Some products contain drug nanocrystals, while others use lipid, polymer, protein, or inorganic carriers. The term describes a formulation feature rather than one pharmacologic class.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is a Nanoparticle Drug?

A nanoparticle drug is a drug product in which the active ingredient or a delivery material is present in particles with nanoscale dimensions or related nanoscale properties. The particles can carry, protect, solubilize, or control the release of a medicine. Some products contain drug nanocrystals, while others use lipid, polymer, protein, or inorganic carriers. The term describes a formulation feature rather than one pharmacologic class.

read more about nanoparticle drug ...

Copy this HTML:

Copy HTML Copied!

What Are Nanoparticle Drugs Used For?

Nanoparticle formulations are used to improve delivery of drugs that have poor solubility, instability, rapid clearance, or difficult tissue distribution. Approved products include selected liposomal medicines, albumin-bound particles, iron-containing particles, and drug nanocrystals. Applications include cancer treatment, infection management, imaging, vaccination, and other therapeutic areas. A nanoparticle formulation can behave differently from a conventional product containing the same active ingredient.

How Do Nanoparticle Drugs Work?

The active drug can be dissolved inside a particle, attached to its surface, trapped within a carrier, or manufactured as the particle itself. Particle size and surface properties influence circulation, uptake by cells, tissue distribution, and interaction with proteins. The formulation can release drug through diffusion, carrier breakdown, lipid exchange, dissolution, or environmental triggers. Not every nanoparticle accumulates selectively in diseased tissue.

What Types of Nanoparticle Drug Formulations Are There?

Common systems include liposomes, lipid nanoparticles, polymeric nanoparticles, micelles, nanoemulsions, albumin-bound particles, nanocrystals, and selected inorganic particles. Each system has different structural and release characteristics. Surface coatings or ligands can be added to change stability, circulation, or cellular uptake. Classification can overlap because a product can have features of more than one nanoscale system.

What Are the Quality and Safety Considerations?

Manufacturers evaluate particle size, size distribution, shape, surface charge, composition, drug loading, release, aggregation, sterility, and stability. Small manufacturing changes can affect biological behavior and clinical performance. Nanoparticles can trigger infusion reactions, immune effects, unexpected tissue accumulation, carrier toxicity, or other product-specific problems. Follow-on or generic development can require detailed comparison beyond measuring the active ingredient alone.

Frequently Asked Questions About Nanoparticle Drugs

Is a nanoparticle drug always a targeted drug?

No. Some formulations alter distribution or uptake without recognizing a specific molecular target. Active targeting requires a validated targeting feature and supporting evidence.

Is a liposomal drug a nanoparticle drug?

Many liposomal drug products are considered nanomaterial-containing formulations because their vesicles have nanoscale dimensions and distinct delivery properties.

Are nanoparticle drugs absorbed differently?

They can have different dissolution, uptake, distribution, metabolism, or clearance from conventional formulations. The effect depends on the route and particle design.

Can two nanoparticle formulations with the same drug be interchangeable?

Not automatically. Differences in carrier, particle properties, release, and manufacturing can change clinical performance. Interchangeability requires the applicable regulatory evidence.

References

Drug Products, Including Biological Products, That Contain Nanomaterials: Guidance for Industry. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-products-including-biological-products-contain-nanomaterials-guidance-industry. Date Accessed August 6, 2026.

Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/liposome-drug-products-chemistry-manufacturing-and-controls-human-pharmacokinetics-and. Date Accessed August 6, 2026.

DOXIL (Doxorubicin Hydrochloride Liposome Injection): Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1c153e9e-4cf2-4ac7-9cf9-16f9b48d7dce. Date Accessed August 6, 2026.

ABRAXANE (Paclitaxel Protein-Bound Particles for Injectable Suspension): Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4. Date Accessed August 6, 2026.

ONPATTRO (Patisiran Lipid Complex Injection): Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e87ec36f-b4b4-49d4-aea4-d4ffb09b0970. Date Accessed August 6, 2026.